Cocrystal Pharma (COCP) EBITDA (2010 - 2026)
Cocrystal Pharma (COCP) posted EBITDA of -$2.4 million for Q1 2026, up 5.04% sequentially from -$2.5 million in Q4 2025, and down 0.64% YoY from -$2.4 million in Q1 2025.
Cocrystal Pharma (COCP) EBITDA (2010 - 2026) Analysis & Trends
Cocrystal Pharma has reported EBITDA for 17 years, with the latest figure at -$2.4 million in Q1 2026.
- Quarterly EBITDA fell 0.64% year-over-year to -$2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.0 million (up 43.75% YoY) and the FY2025 annual result came in at -$9.0 million, up 49.55% from the prior year.
- EBITDA grew to -$2.4 million in Q1 2026 per COCP's latest filing, from -$2.5 million in the prior quarter.
- Over five years, EBITDA peaked at -$2.1 million in Q3 2025 and troughed at -$24.4 million in Q2 2022.
- A 5-year average of -$5.1 million and a median of -$4.3 million in 2023 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2023: EBITDA tumbled 538.14% in 2022, then soared 82.24% in 2023.
- Over 5 years, EBITDA stood at -$4.5 million in 2022, then decreased by 3.64% to -$4.7 million in 2023, then surged by 30.78% to -$3.2 million in 2024, then grew by 23.19% to -$2.5 million in 2025, then gained by 5.04% to -$2.4 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$2.4 million, -$2.5 million, and -$2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 133.12 Mn |
| 10 | Cocrystal Pharma | 16.27 Mn | 13.95 Mn | - | -3.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.18 Mn |
| Mar 31, 2026 | -2.36 Mn |
| Dec 31, 2025 | -2.48 Mn |
| Sep 30, 2025 | -2.09 Mn |
| Jun 30, 2025 | -2.11 Mn |
| Mar 31, 2025 | -2.34 Mn |
| Dec 31, 2024 | -3.23 Mn |
| Sep 30, 2024 | -5.04 Mn |
| Jun 30, 2024 | -5.45 Mn |
| Mar 31, 2024 | -4.16 Mn |
| Dec 31, 2023 | -4.67 Mn |
| Sep 30, 2023 | -4.44 Mn |
| Jun 30, 2023 | -4.34 Mn |
| Mar 31, 2023 | -5.11 Mn |
| Dec 31, 2022 | -4.50 Mn |
| Sep 30, 2022 | -5.69 Mn |
| Jun 30, 2022 | -24.43 Mn |
| Mar 31, 2022 | -4.21 Mn |
| Dec 31, 2021 | -3.70 Mn |
| Sep 30, 2021 | -3.95 Mn |